<p>2025 年 9 月 11 日- 上午 8:35</p>
<p><em><strong>此次交易将 larsucosterol 纳入 Bausch Health 的肝病管线，该药物是 FDA 突破性疗法，用于治疗与酒精相关的肝炎，目前正在进行注册的三期临床试验</strong></em></p>
<p>Bausch Health Companies Inc.（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）（&#34;Bausch Health&#34;）是一家全球多元化的制药公司，今天宣布成功完成其之前宣布的收购 DURECT Corporation（&#34;DURECT&#34;）的要约收购。根据协议条款，Bausch Health 以每股 1.75 美元的现金收购了 DURECT 所有未偿还的股份，总现金支付约为 6300 万美元。该交易还包括在达到某些里程碑之前，可能会有两笔额外的净销售里程碑付款，总额可达 3.5 亿美元（根据保留计划的某些调整）。</p>
<p>此次收购将 DURECT 的主要资产 larsucosterol 纳入 Bausch Health 的肝病管线，larsucosterol 是一种新型的表观遗传调节剂，获得了 FDA 突破性疗法认证，用于治疗与酒精相关的肝炎（&#34;AH&#34;）。目前，没有批准的疗法用于治疗 AH，患者必须依赖如皮质类固醇等支持性治疗，这通常不足以进行长期治疗，并导致约 30% 的患者在住院 90 天内死亡。目前正在计划注册的三期项目，以评估 larsucosterol 在重度 AH 患者治疗中的安全性和有效性。</p>
<p>&#34;我们很高兴完成对 DURECT 的收购，这将 larsucosterol 引入我们的肝病管线，作为一种有前景的先进疗法，&#34;Bausch Health 首席执行官 <strong>Thomas J. Appio</strong> 表示。&#34;对于与酒精相关的肝炎，急需治疗，这种疾病每年导致大量住院。这一补充支持我们在开发针对肝病的创新疗法方面的持续努力，这些疾病目前缺乏或没有治疗选择。此次收购与我们在有目的的研发和推进未满足医疗需求领域解决方案的战略重点相一致。&#34;</p>
<p>DURECT 所有未偿还股份的要约收购于 2025 年 9 月 10 日下午 5:00（纽约市时间）到期。要约收购的存托机构 Equiniti Trust Company, LLC 已通知 Bausch Health，约 19,984,767 股 DURECT 普通股有效投标且未被适当撤回，约占当时 DURECT 普通股的 62%。所有要约收购的条件均已满足，2025 年 9 月 11 日，Bausch Health 的全资子公司（&#34;合并子公司&#34;）接受了有效投标且未被适当撤回的所有股份的付款，并将尽快支付。要约收购完成后，合并子公司根据特拉华州一般公司法第 251(h) 条款与 DURECT 合并，无需 DURECT 股东投票（&#34;合并&#34;），DURECT 继续作为合并存续公司，名称为 DURECT Corporation。在合并中，未在要约收购中投标的 DURECT 股份被转换为每股 1.75 美元现金加上一份 CVR 的权利。</p>
<p>在要约收购和合并完成后，DURECT Corporation 成为 Bausch Health 的全资子公司。在 2025 年 9 月 11 日纳斯达克证券市场（&#34;纳斯达克&#34;）开盘前，所有 DURECT 普通股将在纳斯达克停止交易，DURECT 计划迅速使这些股份从纳斯达克退市，并根据《1934 年证券交易法》进行注销。</p>
<p><strong>顾问</strong></p>
<p>Centerview Partners LLC 担任 Bausch Health 的独家财务顾问，Sullivan &amp; Cromwell LLP 担任其法律顾问。Locust Walk 担任 DURECT 的独家财务顾问，Orrick, Herrington &amp; Sutcliffe LLP 担任其法律顾问。</p>
<p><strong>关于 Bausch Health</strong></p>
<p>Bausch Health Companies Inc.（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）是一家全球多元化的制药公司，通过我们不懈的努力改善医疗保健结果，丰富人们的生活。我们开发、生产和销售一系列产品，主要涉及胃肠病学、肝病学、神经学、皮肤病学、牙科、美容、国际制药和眼健康，通过我们对 Bausch + Lomb Corporation 的控股权益。我们的目标是成为一家全球一体化的医疗保健公司，受到患者、医疗保健专业人士、员工和投资者的信任和重视。我们的胃肠病学业务 Salix Pharmaceuticals 是全球最大的专业制药企业之一，30 多年来一直致力于许可、开发和销售创新产品以治疗胃肠疾病。有关 Salix 的更多信息，请访问 www.Salix.com，并在 Twitter 和 LinkedIn 上与我们联系。有关 Bausch Health 的更多信息，请访问 www.bauschhealth.com，并在 LinkedIn 上与我们联系。</p>
<p><strong>关于 DURECT Corporation</strong></p>
<p>DURECT Corporation 是一家处于后期阶段的生物制药公司，开创性地开发针对失调的 DNA 甲基化的表观遗传疗法，以改变对包括急性器官损伤在内的严重和危及生命的疾病的治疗。DURECT 的主要药物候选物 Larsucosterol 能够结合并抑制 DNA 甲基转移酶的活性，这些表观遗传酶在 AH 患者中升高并与超甲基化相关。Larsucosterol 正在进行临床开发，作为 AH 的潜在治疗，FDA 已授予其快速通道和突破性疗法的资格；MASH 也已被探索。有关 DURECT 的更多信息，请访问 www.durect.com，并在 X（前身为 Twitter）上关注 DURECT，网址为 https://x.com/DURECTCorp。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿可能包含关于与 DURECT 拟议交易及 Bausch Health 未来表现的前瞻性声明（Bausch Health 和 DURECT 统称为 “各方”），通常可以通过使用 “预期”、“希望”、“期望”、“打算”、“计划”、“应该”、“可能”、“会”、“可能”、“相信”、“受限于” 及其变体或类似表达来识别。这些声明基于管理层当前的期望和信念，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中描述的结果有实质性差异。实际结果还受到与各方整体业务更广泛相关的其他风险和不确定性的影响，包括在各方最近的 10-K 表格年报和 10-Q 表格季度报告中更全面描述的那些风险，以及在各方其他向美国证券交易委员会提交的文件中详细说明的风险，Bausch Health 还需遵循加拿大证券管理局的规定，这些因素在此通过引用纳入。此外，这些风险和不确定性包括但不限于以下内容：与 larsucosterol 的成功及其获得监管批准的路径相关的不确定性；净销售里程碑付款的实现；对第三方的依赖，这增加了 larsucosterol 的监管批准提交可能延迟的风险，或者我们可能无法以可接受的成本获得足够数量的 larsucosterol，这可能会延迟、阻止或损害我们对 larsucosterol 的开发和商业化努力；larsucosterol 的未来临床试验可能会延迟，并且可能无法证明其有效性或安全性；以及 larsucosterol 在 AH 中的开放标签试验具有固有的局限性。有关这些重要因素和假设的更多信息，请参见上述各方的文件。这些前瞻性声明仅在本声明日期有效。各方没有义务更新任何这些前瞻性声明，以反映本新闻稿日期之后的事件或情况，或反映实际结果，除非法律要求。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>投资者联系：</strong><br/><strong>Garen Sarafian</strong><br/>ir@bauschhealth.com<br/>(877) 281-6642（免费电话）</td>
<td></td>
<td><strong>媒体联系：</strong><br/><strong>Katie Savastano</strong><br/>corporate.communications@bauschhealth.com<br/>(908) 569-3692</td>
</tr>
</tbody>
</table>
<p><strong>来源：</strong> Bausch Health Companies Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA3MTU1Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA3MTU1Mg"/></p>

<p>Bausch Health 已完成对 DURECT Corporation 的收购，收购价格为每股 1.75 美元，总计约 6300 万美元。这项收购将 larsucosterol（用于治疗与酒精相关的肝炎的 FDA 突破性疗法）纳入 Bausch 的肝病治疗管线。该交易包括高达 3.5 亿美元的潜在里程碑付款。合并后，DURECT 将成为 Bausch Health 的全资子公司，其股票将从纳斯达克退市。这项收购与 Bausch 专注于开发创新肝病疗法的战略相一致</p>

<p>09/11/2025 - 08:35 AM</p>
<div class="lb-trans"><p>2025 年 9 月 11 日- 上午 8:35</p>
</div><p><em><strong>The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline</strong></em></p>
<div class="lb-trans"><p><em><strong>此次交易将 larsucosterol 纳入 Bausch Health 的肝病管线，该药物是 FDA 突破性疗法，用于治疗与酒精相关的肝炎，目前正在进行注册的三期临床试验</strong></em></p>
</div><p>Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (&#34;Bausch Health&#34;), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire DURECT Corporation (&#34;DURECT&#34;). Under the terms of the agreement, Bausch Health acquired all outstanding shares of DURECT for $1.75 per share in cash, representing a total upfront cash payment of approximately $63 million at closing. The transaction also includes the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subject to certain adjustments in respect of a retention plan) if the milestones are achieved before the earlier of the 10-year anniversary of the first commercial sale in the United States and December 31, 2045.</p>
<div class="lb-trans"><p>Bausch Health Companies Inc.（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）（&#34;Bausch Health&#34;）是一家全球多元化的制药公司，今天宣布成功完成其之前宣布的收购 DURECT Corporation（&#34;DURECT&#34;）的要约收购。根据协议条款，Bausch Health 以每股 1.75 美元的现金收购了 DURECT 所有未偿还的股份，总现金支付约为 6300 万美元。该交易还包括在达到某些里程碑之前，可能会有两笔额外的净销售里程碑付款，总额可达 3.5 亿美元（根据保留计划的某些调整）。</p>
</div><p>The acquisition adds DURECT's lead asset, larsucosterol, a novel epigenetic modulator with FDA Breakthrough Therapy Designation for treatment of alcohol-associated hepatitis (&#34;AH&#34;), to Bausch Health's hepatology pipeline. Currently, there are no approved therapies indicated to treat AH, and patients must rely on supportive care such as corticosteroids, which are often inadequate for long-term treatment and result in about 30% mortality within 90 days of hospitalization. A registrational Phase 3 program is currently being planned to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH.</p>
<div class="lb-trans"><p>此次收购将 DURECT 的主要资产 larsucosterol 纳入 Bausch Health 的肝病管线，larsucosterol 是一种新型的表观遗传调节剂，获得了 FDA 突破性疗法认证，用于治疗与酒精相关的肝炎（&#34;AH&#34;）。目前，没有批准的疗法用于治疗 AH，患者必须依赖如皮质类固醇等支持性治疗，这通常不足以进行长期治疗，并导致约 30% 的患者在住院 90 天内死亡。目前正在计划注册的三期项目，以评估 larsucosterol 在重度 AH 患者治疗中的安全性和有效性。</p>
</div><p>&#34;We are pleased to complete the acquisition of DURECT, which brings larsucosterol into our hepatology pipeline as a promising advanced-stage therapy,&#34; said <strong>Thomas J. Appio, Chief Executive Officer, Bausch Health</strong>. &#34;There is an urgent need for treatments for alcohol-associated hepatitis, a disease that leads to a significant number of hospitalizations each year. This addition supports our ongoing efforts to develop innovative therapies for liver diseases with limited or no current treatment options. The acquisition aligns with our strategic focus on purposeful R&amp;D and advancing solutions in areas of unmet medical need.&#34;</p>
<div class="lb-trans"><p>&#34;我们很高兴完成对 DURECT 的收购，这将 larsucosterol 引入我们的肝病管线，作为一种有前景的先进疗法，&#34;Bausch Health 首席执行官 <strong>Thomas J. Appio</strong> 表示。&#34;对于与酒精相关的肝炎，急需治疗，这种疾病每年导致大量住院。这一补充支持我们在开发针对肝病的创新疗法方面的持续努力，这些疾病目前缺乏或没有治疗选择。此次收购与我们在有目的的研发和推进未满足医疗需求领域解决方案的战略重点相一致。&#34;</p>
</div><p>The tender offer for all outstanding shares of DURECT expired at 5:00 p.m., New York City time, on September 10, 2025. Equiniti Trust Company, LLC, the depositary for the tender offer, has advised Bausch Health that approximately 19,984,767 shares of DURECT common stock were validly tendered and not properly withdrawn in the tender offer, representing approximately 62% of the then-outstanding shares of DURECT's common stock. All of the conditions to the tender offer have been satisfied, and on September 11, 2025, a wholly owned subsidiary of Bausch Health (&#34;Merger Sub&#34;) accepted for payment and will as promptly as practicable pay for all shares validly tendered and not properly withdrawn in the tender offer. Following the consummation of the tender offer, Merger Sub merged with and into DURECT in accordance with Section 251(h) of the Delaware General Corporation Law without a vote of DURECT stockholders (the &#34;Merger&#34;), with DURECT continuing as the surviving corporation in the Merger under the name DURECT Corporation. In the Merger, shares of DURECT that were not tendered in the tender offer were converted into the right to receive $1.75 per share in cash plus one CVR.</p>
<div class="lb-trans"><p>DURECT 所有未偿还股份的要约收购于 2025 年 9 月 10 日下午 5:00（纽约市时间）到期。要约收购的存托机构 Equiniti Trust Company, LLC 已通知 Bausch Health，约 19,984,767 股 DURECT 普通股有效投标且未被适当撤回，约占当时 DURECT 普通股的 62%。所有要约收购的条件均已满足，2025 年 9 月 11 日，Bausch Health 的全资子公司（&#34;合并子公司&#34;）接受了有效投标且未被适当撤回的所有股份的付款，并将尽快支付。要约收购完成后，合并子公司根据特拉华州一般公司法第 251(h) 条款与 DURECT 合并，无需 DURECT 股东投票（&#34;合并&#34;），DURECT 继续作为合并存续公司，名称为 DURECT Corporation。在合并中，未在要约收购中投标的 DURECT 股份被转换为每股 1.75 美元现金加上一份 CVR 的权利。</p>
</div><p>Following the closing of the tender offer and Merger, DURECT Corporation became a wholly owned subsidiary of Bausch Health. Prior to the opening of trading on The Nasdaq Stock Market LLC (&#34;Nasdaq&#34;) on September 11, 2025, all shares of DURECT common stock will cease trading on Nasdaq, and DURECT intends to promptly cause such shares to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.</p>
<div class="lb-trans"><p>在要约收购和合并完成后，DURECT Corporation 成为 Bausch Health 的全资子公司。在 2025 年 9 月 11 日纳斯达克证券市场（&#34;纳斯达克&#34;）开盘前，所有 DURECT 普通股将在纳斯达克停止交易，DURECT 计划迅速使这些股份从纳斯达克退市，并根据《1934 年证券交易法》进行注销。</p>
</div><p><strong>Advisors</strong></p>
<div class="lb-trans"><p><strong>顾问</strong></p>
</div><p>Centerview Partners LLC acted as exclusive financial advisor and Sullivan &amp; Cromwell LLP acted as legal advisor to Bausch Health. Locust Walk acted as exclusive financial advisor and Orrick, Herrington &amp; Sutcliffe LLP acted as legal advisor to DURECT.</p>
<div class="lb-trans"><p>Centerview Partners LLC 担任 Bausch Health 的独家财务顾问，Sullivan &amp; Cromwell LLP 担任其法律顾问。Locust Walk 担任 DURECT 的独家财务顾问，Orrick, Herrington &amp; Sutcliffe LLP 担任其法律顾问。</p>
</div><p><strong>About Bausch Health</strong></p>
<div class="lb-trans"><p><strong>关于 Bausch Health</strong></p>
</div><p>Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.</p>
<div class="lb-trans"><p>Bausch Health Companies Inc.（纽约证券交易所代码：BHC）（多伦多证券交易所代码：BHC）是一家全球多元化的制药公司，通过我们不懈的努力改善医疗保健结果，丰富人们的生活。我们开发、生产和销售一系列产品，主要涉及胃肠病学、肝病学、神经学、皮肤病学、牙科、美容、国际制药和眼健康，通过我们对 Bausch + Lomb Corporation 的控股权益。我们的目标是成为一家全球一体化的医疗保健公司，受到患者、医疗保健专业人士、员工和投资者的信任和重视。我们的胃肠病学业务 Salix Pharmaceuticals 是全球最大的专业制药企业之一，30 多年来一直致力于许可、开发和销售创新产品以治疗胃肠疾病。有关 Salix 的更多信息，请访问 www.Salix.com，并在 Twitter 和 LinkedIn 上与我们联系。有关 Bausch Health 的更多信息，请访问 www.bauschhealth.com，并在 LinkedIn 上与我们联系。</p>
</div><p><strong>About DURECT Corporation</strong></p>
<div class="lb-trans"><p><strong>关于 DURECT Corporation</strong></p>
</div><p>DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Breakthrough Therapy designation; MASH has also been explored. For more information about DURECT, please visit www.durect.com and follow DURECT on X (formerly Twitter) at https://x.com/DURECTCorp.</p>
<div class="lb-trans"><p>DURECT Corporation 是一家处于后期阶段的生物制药公司，开创性地开发针对失调的 DNA 甲基化的表观遗传疗法，以改变对包括急性器官损伤在内的严重和危及生命的疾病的治疗。DURECT 的主要药物候选物 Larsucosterol 能够结合并抑制 DNA 甲基转移酶的活性，这些表观遗传酶在 AH 患者中升高并与超甲基化相关。Larsucosterol 正在进行临床开发，作为 AH 的潜在治疗，FDA 已授予其快速通道和突破性疗法的资格；MASH 也已被探索。有关 DURECT 的更多信息，请访问 www.durect.com，并在 X（前身为 Twitter）上关注 DURECT，网址为 https://x.com/DURECTCorp。</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This news release may contain forward-looking statements about the proposed transaction with DURECT and the future performance of Bausch Health (Bausch Health and DURECT, collectively, &#34;the Parties&#34;), which may generally be identified by the use of the words &#34;anticipates,&#34; &#34;hopes,&#34; &#34;expects,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;should,&#34; &#34;could,&#34; &#34;would,&#34; &#34;may,&#34; &#34;believes,&#34; &#34;subject to&#34; and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the Parties' overall businesses, including those more fully described in the Parties' most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and detailed from time to time in the Parties' other filings with the U.S. Securities and Exchange Commission and, in the case of Bausch Health, the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, such risks and uncertainties include, but are not limited to, the following: uncertainties relating to the success of larsucosterol and its path to regulatory approval; achievement of the net sales milestone payments; reliance on third parties, which increases the risk that submissions for regulatory approval of larsucosterol may be delayed or that we will not have sufficient quantities of larsucosterol available at an acceptable cost, which could delay, prevent or impair our development and commercialization efforts of larsucosterol; future clinical trials for larsucosterol may be delayed and may not demonstrate efficacy or safety; and open-label trials of larsucosterol in AH have inherent limitations. Additional information regarding certain of these material factors and assumptions may be found in the Parties' filings described above. These forward-looking statements speak only as of the date hereof. The Parties undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.</p>
<div class="lb-trans"><p>本新闻稿可能包含关于与 DURECT 拟议交易及 Bausch Health 未来表现的前瞻性声明（Bausch Health 和 DURECT 统称为 “各方”），通常可以通过使用 “预期”、“希望”、“期望”、“打算”、“计划”、“应该”、“可能”、“会”、“可能”、“相信”、“受限于” 及其变体或类似表达来识别。这些声明基于管理层当前的期望和信念，并受到某些风险和不确定性的影响，这些风险和不确定性可能导致实际结果与前瞻性声明中描述的结果有实质性差异。实际结果还受到与各方整体业务更广泛相关的其他风险和不确定性的影响，包括在各方最近的 10-K 表格年报和 10-Q 表格季度报告中更全面描述的那些风险，以及在各方其他向美国证券交易委员会提交的文件中详细说明的风险，Bausch Health 还需遵循加拿大证券管理局的规定，这些因素在此通过引用纳入。此外，这些风险和不确定性包括但不限于以下内容：与 larsucosterol 的成功及其获得监管批准的路径相关的不确定性；净销售里程碑付款的实现；对第三方的依赖，这增加了 larsucosterol 的监管批准提交可能延迟的风险，或者我们可能无法以可接受的成本获得足够数量的 larsucosterol，这可能会延迟、阻止或损害我们对 larsucosterol 的开发和商业化努力；larsucosterol 的未来临床试验可能会延迟，并且可能无法证明其有效性或安全性；以及 larsucosterol 在 AH 中的开放标签试验具有固有的局限性。有关这些重要因素和假设的更多信息，请参见上述各方的文件。这些前瞻性声明仅在本声明日期有效。各方没有义务更新任何这些前瞻性声明，以反映本新闻稿日期之后的事件或情况，或反映实际结果，除非法律要求。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Investor Contact:</strong><br/><strong>Garen Sarafian</strong><br/>ir@bauschhealth.com<br/>(877) 281-6642 (toll free)</td>
<td></td>
<td><strong>Media Contact:</strong><br/><strong>Katie Savastano</strong><br/>corporate.communications@bauschhealth.com<br/>(908) 569-3692</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>投资者联系：</strong><br/><strong>Garen Sarafian</strong><br/>ir@bauschhealth.com<br/>(877) 281-6642（免费电话）</td>
<td></td>
<td><strong>媒体联系：</strong><br/><strong>Katie Savastano</strong><br/>corporate.communications@bauschhealth.com<br/>(908) 569-3692</td>
</tr>
</tbody>
</table>
</div><p><strong>SOURCE:</strong> Bausch Health Companies Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> Bausch Health Companies Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTA3MTU1Mg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1071552"/></p>

Bausch Health 完成了对 DURECT 公司的收购，扩展了其晚期肝病产品组合 | BHC 股票新闻